Stimulation of human platelet adenylate cyclase by the diterpene forskolin is associated with a decrease in the apparent substrate (MgATP) affinity of the enzyme. Addition of the stimulatory hormone prostaglandin E1 not only further increased the Vmax. of the forskolin-stimulated platelet adenylate cyclase but also caused a further increase in the Km value for MgATP, by up to 20-fold compared with basal conditions. On the other hand, the inhibitory hormone adrenaline decreased not only the Vmax. but also the Km value of the platelet adenylate cyclase stimulated by forskolin, with or without prostaglandin E1 present. The data indicate that forskolin sensitizes human platelet adenylate cyclase to modulation of substrate (MgATP) affinity by hormones, but there is no such effect in the absence of the diterpene.
INTRODUCTION
The hormone-sensitive adenylate cyclase system is composed of several interacting subunits embedded in the lipid bilayer of the plasma membrane: stimulatory and inhibitory hormone receptors, acting as external discriminators, the adenylate cyclase catalytic moiety, catalysing the formation of cyclic AMP from MgATP, and two guanine nucleotide-binding regulatory com- ponents, N. and Ni, transducing the signal from the hormone-activated stimulatory and inhibitory receptors respectively to the adenylate cyclase (Gilman, 1984; Birnbaumer et al., 1985) . Modulation of adenylate cyclase activity by hormone-and guanine nucleotideactivated Ns and Ni is associated with changes in the affinity of the adenylate cyclase for its activating cation Mg2+ (Cech et al., 1980; Iyengar & Birnbaumer, 1982; Jakobs et al., 1983; Bockaert et al., 1984) . However, a change in the affinity of the adenylate cyclase for its substrate, MgATP, by hormone-and guanine nucleotideactivated Ns and Ni has not been described so far.
By-passing the hormone receptors and probably also the N. component, the hormone-sensitive adenylate cyclase can be stimulated by the diterpene forskolin (Seamon & Daly, 1981; Daly, 1984 equimolar concentrations (10-500,M), 2 mm excess MgCl2, 0.1 mM-EGTA, 1 mM-3-isobutyl-1-methylxanthine, 0.1 mM-cyclic AMP, 1 mM-dithiothreitol, 5 mmphosphocreatine, 0.4 mg of creatine kinase/ml, 1 mg of bovine serum albumin/ml, 1 ,uM-GTP and the additions indicated in 50 mM-triethanolamine/HCl, pH 7.4. The reactions were conducted for 10 min at 37°C in a total volume of 100,1, with 5-15,ug of platelet membrane protein per tube. Cyclic AMP formed was isolated as described by Jakobs et al. (1976) . The assays were performed in triplicate, with an intra-assay variation of less than 10% of the means. Fig. 1 shows results of individual experiments, which were repeated six or seven times in a similar manner with different membrane preparations and with different MgATP concentrations (see Table 1 ). Km and Vmax values were estimated from linear double-reciprocal plots of substrate concentration versus enzyme activity.
RESULTS
In the absence of stimulatory and inhibitory ligands, adenylate cyclase of human platelet membranes exhibited a Km value for MgATP of 15-20 /M (Fig. la) (Jakobs et al., 1978; Johnson et al., 1979; Awad et al., 1983) . The inhibitory hormone adrenaline (30 gM) decreased basal platelet adenylate cyclase activity by more than 50%.
This decrease in activity was not associated with a change in the Km value of the platelet adenylate cyclase for its substrate, MgATP. The stimulatory hormone PGE1 (3 /aM) caused a large increase in adenylate cyclase activity (Fig. lb) . This increase in activity was also not associated with a significant change in the Km value of the enzyme for MgATP. Additonally, adrenaline (30 /M) decreased the PGE,-stimulated activity by more than 50% without causing a significant change in the Km value for MgATP. Thus, as reported previously (Jakobs et al., 1978; Johnson et al., 1979) , the stimulatory and inhibitory hormones PGE1 and adrenaline increase and decrease, respectively, the activity of human platelet adenylate cyclase without significant changes in the Modulation of adenylate cyclase substrate affinity (Jakobs et al., 1978; Johnson et al., 1979) , the stimulatory and inhibitory hormones PGE1 and adrenaline increase and decrease, respectively, human platelet adenylate cyclase activity without affecting the apparent affinity of the enzyme for its substrate MgATP. However, in the presence of forskolin, which by itself decreased the platelet enzyme's affinity for MgATP (Awad et al., 1983) , PGE1 and adrenaline not only induced changes in the Vmax of the enzyme but also increased and decreased, respectively, the Km value of adenylate cyclase for its substrate MgATP. To our knowledge, this is the first example where a hormonal effect on the apparent affinity of adenylate cyclase for its substrate MgATP has been described. The intriguing question is how these changes in apparent substrate affinity by forskolin and, in the presence of forskolin, by hormone-activated N. (PGE1) and N1 (adrenaline) are accomplished. It may be speculated that there are two binding sites for forskolin in the platelet adenylate cyclase system, one at the substrate-binding site, where forskolin may competitively interact with MgATP and lead to the observed increase in the MgATP Km value, and another allosteric binding site leading to the observed increase in the Vmax. of the enzyme by forskolin. These two sites may exhibit different sensitivities to forskolin. However, as described previously (Awad et al., 1983) , there was no major dissociation between the decrease in apparent substrate affinity of basal adenylate cyclase and the increase in the catalytic activity of the platelet enzyme by forskolin. Furthermore, as shown in above, the observed concomitant increase in both Km value for MgATP and Vmax of the forskolin-stimulated adenylate cyclase by hormoneactivated Ns argues a simple competitive interaction of forskolin with MgATP at the substrate binding site.
Additionally, hormone-activated Ni decreased not only Vmax but also the Km value for MgATP when forskolin was present. However, without forskolin present, neither hormone-activated Ns nor Ni by themselves significantly affected the apparent MgATP affinity of the platelet adenylate cyclase. Thus it appears that forskolin, by an action at one binding site of the system, induces both activation of the adenylate cyclase and a decrease in the apparent affinity of the enzyme for its substrate MgATP, and that both effects of forskolin are facilitated and hindered by hormone-and guanine nucleotide-activated Ns and Ni respectively. The elucidation of the underlying mechanisms obviously requires studies with resolved components of the system.
The data presented herein should also serve as a cautionary note that, when forskolin is used as a platelet adenylate cyclase-activating agent in combination with stimulatory or inhibitory hormonal agents, the hormonal effects may be masked by concomitant changes in the substrate affinity of the platelet adenylate cyclase. This may explain, e.g., why the platelet adenylate cyclase stimulated by forskolin plus PGE1, then apparently exhibiting extremely low substrate affinity, seemed to be less sensitive to inhibition by adrenaline than the enzyme stimulated by PGE1 or forskolin alone when activity was measured at one concentration of MgATP (Insel et al. 1982) . On the other hand, the stimulatory effect of forskolin measured on basal adenylate cyclase activity, and particularly in the presence of a stimulatory hormone such as PGE1, may be masked when using relatively low substrate concentrations.
